MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Lawsuit Filed by the Schall Law Firm

Group 1 - A class action lawsuit has been filed against Marinus Pharmaceuticals, Inc. for violations of the Securities Exchange Act of 1934 [5] - The lawsuit alleges that Marinus made false and misleading statements regarding the risks associated with its RAISE trial, specifically underestimating the potential for failure [7] - The company failed to disclose that not meeting early stopping criteria in the RAISE trial could halt the separate Phase 3 RAISE II trial, leading to materially misleading public statements [7] Group 2 - Investors who purchased Marinus securities between March 17, 2021, and May 7, 2024, are encouraged to contact the Schall Law Firm before August 5, 2024, to discuss their rights [2] - The class has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3] - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [8]